Cargando…

Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells

Introduction: Cyclin D1 (D1) binds to cyclin-dependent kinases (CDK) 4 or 6 to form a holoenzyme that phosphorylates the Rb protein to promote cell cycle progression from G1 to S phase. Therefore, targeting CDK4/6 may be a good strategy for chemotherapy of cancer. We performed a proof-of-principle s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yuan, Li, Ying-xia, Wu, Hai-jun, Wu, Si-hung, Wang, Y. Alan, Luo, Dian-zhong, Liao, D. Joshua
Formato:	Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2011
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020360/ https://www.ncbi.nlm.nih.gov/pubmed/21234300

Ejemplares similares

A new indolocarbazole derivative in melanoma and carcinoma lung in vivo treatment
por: Lantsova, Anna, et al.
Publicado: (2021)

Antikinetoplastid Activity of Indolocarbazoles from Streptomyces sanyensis
por: Cartuche, Luis, et al.
Publicado: (2020)

Cytotoxic Indolocarbazoles From a Marine-Derived Streptomyces Sp. OUCMDZ-5380
por: Cui, Tongxu, et al.
Publicado: (2022)

Combined 3D-QSAR and Docking Modelling Study on Indolocarbazole Series Compounds as Tie-2 Inhibitors
por: Tian, Yuanxin, et al.
Publicado: (2011)

Developing a Novel Indolocarbazole as Histone Deacetylases Inhibitor against Leukemia Cell Lines
por: Wang, Wenjing, et al.
Publicado: (2015)

The phase transitions of 4-aminopyridine-based indolocarbazoles: twinning, local- and pseudo-symmetry
por: Kader, Thomas, et al.
Publicado: (2019)

Precursor-Directed Generation of Indolocarbazoles with Topoisomerase IIα Inhibitory Activity
por: Wang, Cong, et al.
Publicado: (2018)

Antiamoebic Activities of Indolocarbazole Metabolites Isolated from Streptomyces sanyensis Cultures
por: Cartuche, Luis, et al.
Publicado: (2019)

Tuning the Diradical Character of Indolocarbazoles: Impact of Structural Isomerism and Substitution Position
por: Badía-Domínguez, Irene, et al.
Publicado: (2022)

Antioxidants cause rapid expansion of human adipose-derived mesenchymal stem cells via CDK and CDK inhibitor regulation
por: Sun, Li-Yi, et al.
Publicado: (2013)

ED‐110, a Novel Indolocarbazole, Prevents the Growth of Experimental Tumors in Mice
por: Arakawa, Hiroharu, et al.
Publicado: (1993)

Cloning, Characterization and Heterologous Expression of the Indolocarbazole Biosynthetic Gene Cluster from Marine-Derived Streptomyces sanyensis FMA
por: Li, Tong, et al.
Publicado: (2013)

Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269
por: Zenkov, Roman G., et al.
Publicado: (2021)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

Antimetastatic Effect of a Novel Indolocarbazole (NB‐506) on IMC‐HM Murine Tumor Cells Metastasized to the Liver
por: Arakawa, Hiroharu, et al.
Publicado: (1996)

Indolocarbazole-Based Photo-Crosslinkable Hole-Transporting Layer for Efficient Solution-Processed Organic Light-Emitting Diodes
por: Park, Jeong Yong, et al.
Publicado: (2023)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

In vivo Anti‐tumor Activity of a Novel Indolocarbazole Compound, J‐107088, on Murine and Human Tumors Transplanted into Mice
por: Arakawa, Hiroharu, et al.
Publicado: (1999)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Evaluation of Indolocarbazoles from Streptomyces sanyensis as a Novel Source of Therapeutic Agents against the Brain-Eating Amoeba Naegleria fowleri
por: Rizo-Liendo, Aitor, et al.
Publicado: (2020)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
por: Mohammed, Amrallah A., et al.
Publicado: (2019)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
por: Dang, Fabin, et al.
Publicado: (2021)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
por: Zhou, Fiona H., et al.
Publicado: (2023)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Scheidemann, Erin R., et al.
Publicado: (2021)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer()
por: Loibl, Sibylle, et al.
Publicado: (2021)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
por: Liang, Hanzhi, et al.
Publicado: (2022)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eo1nr7u5c654b87lsp73lguh7j